

# Salvatore Petta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2788809/publications.pdf>

Version: 2024-02-01

310  
papers

17,049  
citations

13865

67  
h-index

17592

121  
g-index

317  
all docs

317  
docs citations

317  
times ranked

15341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
2	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	3.7	676
3	Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 1253-1260.e4.	1.3	604
4	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.4	524
5	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , 2016, 150, 1219-1230.e6.	1.3	506
6	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015, 61, 506-514.	7.3	424
7	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1158-1167.	7.3	371
8	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
9	Statin use and non-alcoholic steatohepatitis in at risk individuals. <i>Journal of Hepatology</i> , 2015, 63, 705-712.	3.7	309
10	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	1.0	296
11	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	1.3	291
12	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
13	Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. <i>Journal of Internal Medicine</i> , 2018, 283, 356-370.	6.0	256
14	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
15	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 2016, 63, 2032-2043.	7.3	239
16	Non-alcoholic fatty liver disease pathogenesis: The present and the future. <i>Digestive and Liver Disease</i> , 2009, 41, 615-625.	0.9	222
17	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
18	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205

#	ARTICLE	IF	CITATIONS
19	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	1.3	201
20	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
21	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
22	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
23	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	7.3	183
24	Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 2112-2120.	0.4	177
25	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	7.3	177
26	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1136-1144.	0.4	170
27	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 510-518.	3.7	169
28	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015, 62, 928-933.	3.7	162
29	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
30	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1604-1611.e1.	4.4	146
31	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	3.7	138
32	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
33	Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1350-1360.	3.7	126
34	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
35	Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 757-766.	3.7	125
36	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	3.7	124

#	ARTICLE	IF	CITATIONS
37	The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573.	3.9	116
38	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	7.3	113
39	Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885.	3.7	113
40	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
41	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
42	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
43	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690.	3.7	106
44	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
45	Association Between PNPLA3 rs738409 >G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
46	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
47	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	3.7	98
48	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860.	7.3	97
49	Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 238-247.	3.7	97
50	Early Menopause Is Associated With Lack of Response to Antiviral Therapy in Women With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 818-829.e2.	1.3	96
51	Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010, 52, 1543-1552.	7.3	95
52	The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. <i>Hepatology</i> , 2016, 63, 787-798.	7.3	93
53	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	4.4	90
54	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1046-1054.	7.3	89

#	ARTICLE	IF	CITATIONS
55	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports, 2019, 1, 188-198.	4.9	86
56	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	3.3	85
57	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 65-71.	3.7	83
58	IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2012, 56, 1356-1362.	3.7	82
59	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	1.3	82
60	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. Journal of Hepatology, 2018, 69, 1155-1163.	3.7	80
61	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020, 296, 40-47.	0.8	78
62	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2014, 59, 1692-1705.	7.3	75
63	Interferon lambda 4 rs368234815 TT&gt;T variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	7.3	75
64	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 58, 771-777.	3.7	74
65	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 2017, 65, 1840-1850.	7.3	74
66	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver International, 2018, 38, 2060-2068.	3.9	72
67	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	1.8	71
68	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver International, 2011, 31, 507-515.	3.9	70
69	A meta-analysis of single <sc>HCV</sc>-untreated arm of studies evaluating outcomes after curative treatments of <sc>HCV</sc>-related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	3.9	70
70	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <sc>HCV</sc> eradication does not depend on the use of interferon. Alimentary Pharmacology and Therapeutics, 2017, 45, 160-168.	3.7	70
71	Insulin-Like Growth Factor-I, Inflammatory Proteins, and Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E304-E308.	3.6	69
72	Cardiovascular diseases and HCV infection: a simple association or more?. Gut, 2014, 63, 369-375.	12.1	67

#	ARTICLE	IF	CITATIONS
73	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	3.7	67
74	The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1181-1191.	3.7	66
75	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308.	4.4	66
76	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	3.3	66
77	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
78	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	7.3	66
79	Anti-Tissue Transglutaminase Antibodies in Patients with Abnormal Liver Tests: Is It Always Coeliac Disease?. <i>American Journal of Gastroenterology</i> , 2005, 100, 2472-2477.	0.4	65
80	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009, 49, 195-203.	7.3	65
81	Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e44624.	2.5	63
82	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0163069.	2.5	63
83	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association. <i>Current Pharmaceutical Design</i> , 2010, 16, 741-752.	1.9	61
84	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089.	2.5	59
85	Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS. <i>PLoS ONE</i> , 2017, 12, e0186136.	2.5	59
86	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	4.4	59
87	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416.	4.4	58
88	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
89	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.9	56
90	Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008, 48, 28-37.	7.3	55

#	ARTICLE	IF	CITATIONS
91	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
92	Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1037-46.	2.4	52
93	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Liver International</i> , 2019, 39, 1742-1754.	3.9	51
94	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 486-493.	2.0	49
95	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1325-1334.	3.9	48
96	Ultra-processed food is associated with features of metabolic syndrome and non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2635-2645.	3.9	46
97	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016, 95, e3446.	1.0	44
98	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	3.9	44
99	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
100	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018, 17, 28.	6.8	43
101	Fibronectin Type III Domain-Containing Protein 5 rs3480 A&G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	3.6	42
102	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. <i>Journal of Lipid Research</i> , 2019, 60, 1144-1153.	4.2	42
103	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 658-666.	3.7	41
104	The UCP2 $\beta$ -casein promoter region polymorphism is associated with nonalcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1574-1580.	3.9	41
105	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.	3.8	41
106	Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0142210.	2.5	40
107	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015, 11, 2923-2936.	2.4	40
108	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	2.6	40

#	ARTICLE	IF	CITATIONS
109	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5613.	4.1	39
110	Is global elimination of <sc>HCV</sc> realistic?. <i>Liver International</i> , 2018, 38, 40-46.	3.9	38
111	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	4.3	38
112	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020, 40, 1545-1555.	3.9	37
113	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017, 12, e0185728.	2.5	37
114	MAFLD vs NAFLD: Let the contest begin!. <i>Liver International</i> , 2020, 40, 2079-2081.	3.9	34
115	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	3.7	33
116	Current and future <sc>HCV</sc> therapy: do we still need other anti-â€<sc>HCV</sc> drugs?. <i>Liver International</i> , 2015, 35, 4-10.	3.9	33
117	Hepatitis C virus and cardiovascular: A review. <i>Journal of Advanced Research</i> , 2017, 8, 161-168.	9.5	32
118	Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. <i>Journal of Hepatology</i> , 2009, 50, 648-651.	3.7	31
119	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	4.9	31
120	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	4.4	30
121	Vitamin D Levels and IL28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2012, 17, 823-831.	1.0	29
122	Serum Î³-glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165.	2.5	29
123	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
124	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 193-200.	3.6	28
125	Is there an â€™idealâ€™ diet for patients with NAFLD?. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13659.	3.4	28
126	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410.	0.9	27



#	ARTICLE	IF	CITATIONS
127	The cheating liver: imaging of focal steatosis and fatty sparing. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 671-678.	3.0	27
128	Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, e694-e701.	5.8	27
129	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. <i>BioMed Research International</i> , 2013, 2013, 1-12.	1.9	26
130	NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e68364.	2.5	26
131	<i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.	3.9	26
132	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1014-1022.	2.6	24
133	Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 603-613.	3.7	22
134	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-7.	1.4	22
135	Usefulness of the index of NASH vs ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	3.9	22
136	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-639.	1.0	22
137	AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1293-1302.e5.	4.4	22
138	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.	2.6	21
139	Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008, 15, 523-530.	2.0	20
140	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011, 18, e372-80.	2.0	20
141	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
142	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , 2012, 32, 1443-1450.	3.9	19
143	How to optimize HCV therapy in genotype 1 patients: predictors of response. <i>Liver International</i> , 2013, 33, 23-29.	3.9	19
144	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.9	19

#	ARTICLE	IF	CITATIONS
145	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2018, 68, 33-41.	3.7	19
146	Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 777-787.e17.	4.4	19
147	<sc>PNPLA</sc>3 rs738409 1748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 939-948.	3.7	18
148	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	3.7	18
149	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	9.6	18
150	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.	0.9	17
151	Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. <i>Liver International</i> , 2016, 36, 1765-1773.	3.9	17
152	A <sc>STAT</sc>4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 564-573.	3.7	17
153	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020, 40, 2820-2827.	3.9	17
154	Serum BLYS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 397-405.	2.0	16
155	Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 740-749.	3.7	16
156	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 604.	3.5	16
157	Liver and Statins: A Critical Appraisal of the Evidence. <i>Current Medicinal Chemistry</i> , 2019, 25, 5835-5846.	2.4	16
158	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 174-182.	2.0	15
159	<i><sc>TM</sc>6<sc>SF</sc>2</i> rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	3.9	15
160	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
161	Extrahepatic Manifestations of Chronic Viral C Hepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 347-360.	2.2	15
162	PSD3 downregulation confers protection against fatty liver disease. <i>Nature Metabolism</i> , 2022, 4, 60-75.	11.9	15

#	ARTICLE	IF	CITATIONS
163	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15
164	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	4.4	13
165	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.9	13
166	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	3.0	13
167	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
168	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	1.0	13
169	Management of liver disease in Italy after one year of the SARS-CoV2 pandemic: A web-based survey. <i>Liver International</i> , 2021, 41, 2228-2232.	3.9	13
170	Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 5193-5218.	1.9	13
171	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	1.3	13
172	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. <i>JHEP Reports</i> , 2022, 4, 100444.	4.9	13
173	Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. <i>Antiviral Therapy</i> , 2012, 17, 111-118.	1.0	12
174	Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 465-472.	2.0	12
175	Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance. <i>Hepatitis Monthly</i> , 2013, 13, e7176.	0.2	12
176	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016, 17, 328-334.	4.1	12
177	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519.	4.4	12
178	Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV monoinfected patients. <i>HIV Medicine</i> , 2020, 21, 96-108.	2.2	12
179	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	2.4	12
180	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12

#	ARTICLE	IF	CITATIONS
181	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , 2012, 44, 245-250.	0.9	11
182	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020, 71, 2810-2817.	5.8	11
183	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-CHCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	2.0	11
184	Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021, 40, 407-416.	2.3	11
185	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.9	11
186	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. <i>Current Pharmaceutical Design</i> , 2013, 19, 5297-313.	1.9	11
187	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015, 33, 668-674.	1.9	10
188	Coffee and tea breaks for liver health. <i>Journal of Hepatology</i> , 2017, 67, 221-223.	3.7	10
189	Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158765.	2.4	10
190	Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. <i>Advanced Science</i> , 2021, 8, 2004168.	11.2	10
191	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.	4.4	10
192	NAFLD/NASH. <i>Journal of Hepatology</i> , 2022, 77, 549-550.	3.7	10
193	Optimal therapy in hepatitis C virus genotypes 2 and 3 patients. <i>Liver International</i> , 2011, 31, 36-44.	3.9	9
194	Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?. <i>BMC Infectious Diseases</i> , 2012, 12, S3.	2.9	9
195	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
196	Reply. <i>Hepatology</i> , 2015, 62, 660-660.	7.3	9
197	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. <i>Digestive and Liver Disease</i> , 2020, 52, 359-367.	0.9	9
198	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020, 26, 1110-1118.	1.9	9

#	ARTICLE	IF	CITATIONS
199	Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 1276.	1.8	8
200	Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015, 82, 48-52.	3.8	8
201	Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease. <i>Antiviral Therapy</i> , 2018, 23, 35-46.	1.0	8
202	Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: Spectators or actors?. <i>Digestive and Liver Disease</i> , 2012, 44, 359-360.	0.9	7
203	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
204	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2103-2110.	2.6	7
205	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.9	7
206	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.9	7
207	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-9.	1.0	7
208	Evidence-Based Medicine and the Problem of Healthy Volunteers. <i>Annals of Hepatology</i> , 2017, 16, 832-834.	1.5	6
209	Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FIS (HEpatitis C Virus Fingerstick) Tj ETQq1.10.784314 rgBT (Dx)	3.9	6
210	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307.	0.9	6
211	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.	2.8	6
212	rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.	3.9	6
213	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.	4.3	6
214	Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e60.	0.9	5
215	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> . 2018. 50. 1133-1152.	0.9	5
216	Genetic variants in the MTHFR are not associated with fatty liver disease. <i>Liver International</i> , 2020, 40, 1934-1940.	3.9	5

#	ARTICLE	IF	CITATIONS
217	Na <sup>+</sup> ve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. <i>World Journal of Gastroenterology</i> , 2021, 27, 5112-5125.	3.3	5
218	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020, 73, S13-S14.	3.7	4
219	A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.	3.9	4
220	Reply to: rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. <i>Journal of Hepatology</i> , 2013, 58, 403-404.	3.7	3
221	Epicardial fat in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, 1215.	3.7	3
222	MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2016, 48, e7-e8.	0.9	3
223	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Journal of Nephrology</i> , 2018, 31, 685-712.	2.0	3
224	FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019, 51, e26.	0.9	3
225	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 975-985.	0.4	3
226	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	1.9	3
227	Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0243590.	2.5	3
228	LifeStyle versus Ezetimibe plus lifestyle in patients with biopsy-proven Non-alcoholic steatohepatitis (LISTEN): a double-blind randomised placebo-controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	3
229	Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 5193-218.	1.9	3
230	Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?. <i>Hepatology</i> , 2012, 55, 1309-1309.	7.3	2
231	Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs). <i>Digestive and Liver Disease</i> , 2017, 49, e59.	0.9	2
232	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018, 13, 1139-1166.	2.0	2
233	P162 Prevalence of nafld (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S219-S220.	1.3	2
234	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2

#	ARTICLE	IF	CITATIONS
235	Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women. <i>World Journal of Gastroenterology</i> , 2014, 20, 16726.	3.3	2
236	Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101925.	1.5	2
237	Reply. <i>Hepatology</i> , 2008, 48, 1725-1726.	7.3	1
238	Visceral adiposity index and exercise in nonalcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 490-490.	3.7	1
239	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". <i>Journal of Hepatology</i> , 2014, 60, 677-678.	3.7	1
240	Reply. <i>Hepatology</i> , 2015, 61, 1097-1097.	7.3	1
241	HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study. <i>Digestive and Liver Disease</i> , 2016, 48, e6-e7.	0.9	1
242	Reply to "Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis". <i>Journal of Hepatology</i> , 2016, 64, 984-985.	3.7	1
243	High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment. <i>Digestive and Liver Disease</i> , 2017, 49, e65-e66.	0.9	1
244	Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization (HCRU) and costs: results from Italian administrative databases. <i>Digestive and Liver Disease</i> , 2019, 51, e27.	0.9	1
245	Characterizing compensated cirrhosis (CC) patients with potential etiology of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH): findings from large Italian administrative databases. <i>Digestive and Liver Disease</i> , 2019, 51, e49-e50.	0.9	1
246	Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020, 40, 530-538.	3.9	1
247	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Journal of Hepatology</i> , 2020, 73, S751-S752.	3.7	1
248	Increased serum ferritin levels predict long-term mortality in patients with NAFLD. <i>Digestive and Liver Disease</i> , 2021, 53, S28.	0.9	1
249	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2022, 54, 1117-1121.	0.9	1
250	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
251	P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i236-i236.	1.3	1
252	Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome. <i>Digestive and Liver Disease</i> , 2008, 40, A1-A2.	0.9	0

#	ARTICLE	IF	CITATIONS
253	Retinol-binding protein 4 (RBP4): A new marker of G1 HCV-induced steatosis. Digestive and Liver Disease, 2008, 40, A29-A30.	0.9	0
254	Reply:. Hepatology, 2009, 49, 1394-1395.	7.3	0
255	Reply:. Hepatology, 2009, 49, 1776-1776.	7.3	0
256	Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy. Hepatology, 2010, 51, 1858-1858.	7.3	0
257	Reply:. Hepatology, 2010, 51, 2230-2230.	7.3	0
258	658 HCV CONTRIBUTES TO INDUCE HEPATIC STEATOSIS DEREGULATING LIPID METABOLISM THROUGH LXR DEPENDENT GENES MODULATION. Journal of Hepatology, 2010, 52, S256-S257.	3.7	0
259	Is liver stiffness measurement unreliable in obese patients? authors'™ reply. Alimentary Pharmacology and Therapeutics, 2011, 34, 255-256.	3.7	0
260	Hyperuricemia in non-alcoholic fatty liver disease: authors'™ reply. Alimentary Pharmacology and Therapeutics, 2011, 34, 1043-1044.	3.7	0
261	Reply. Hepatology, 2013, 57, 422-422.	7.3	0
262	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2013, 45, e371.	0.9	0
263	Reply to: "œls industrial fructose just a marker of an unhealthy dietary pattern?" Journal of Hepatology, 2014, 61, 173-175.	3.7	0
264	MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, e2.	0.9	0
265	The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection. Digestive and Liver Disease, 2014, 46, e20.	0.9	0
266	Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD. Digestive and Liver Disease, 2015, 47, e225.	0.9	0
267	Chronic Intermittent Hypoxia is associated with Liver Damage and Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease. Digestive and Liver Disease, 2015, 47, e48-e49.	0.9	0
268	Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study. Digestive and Liver Disease, 2015, 47, e224-e225.	0.9	0
269	Response to Dr. Sertoglu and Colleagues. Liver International, 2015, 35, 285-286.	3.9	0
270	The presence of white matter lesions is associated with the histological severity of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2015, 47, e228.	0.9	0



#	ARTICLE	IF	CITATIONS
271	Reply. <i>Hepatology</i> , 2016, 63, 1394-1394.	7.3	0
272	Reply. <i>Hepatology</i> , 2016, 64, 701-701.	7.3	0
273	Reply. <i>Hepatology</i> , 2017, 65, 2128-2128.	7.3	0
274	Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, e17.	0.9	0
275	Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 31.	0.9	0
276	Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells. <i>Digestive and Liver Disease</i> , 2018, 50, 28-29.	0.9	0
277	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Digestive and Liver Disease</i> , 2018, 50, 58.	0.9	0
278	Noninvasive prediction of esophageal varices by liver stiffness measurement and platelet values in patients with liver cirrhosis due to nonalcoholic fatty liver disease: A multicenter cross-sectional study. <i>Digestive and Liver Disease</i> , 2018, 50, 3-4.	0.9	0
279	Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2018, 50, 19.	0.9	0
280	Can we prevent and modify cardiometabolic disorders by controlling HCV infection?. <i>Gut</i> , 2018, 67, 403-404.	12.1	0
281	Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2018, 69, 1203-1204.	3.7	0
282	HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy. <i>Journal of Hepatology</i> , 2018, 68, S255-S256.	3.7	0
283	THU-335-FXR rs35724 C > G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2019, 70, e307-e308.	3.7	0
284	Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort. <i>Digestive and Liver Disease</i> , 2019, 51, e262-e263.	0.9	0
285	PS-061-Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis patients with advanced liver disease had high burden of comorbidities, healthcare resource utilization and costs: Results from Italian administrative databases. <i>Journal of Hepatology</i> , 2019, 70, e37.	3.7	0
286	Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity. <i>Digestive and Liver Disease</i> , 2019, 51, e4.	0.9	0
287	Effects of HCV eradication by DAA on oxidative stress parameters in patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2019, 51, e59.	0.9	0
288	PNPLA3 rs738409 C > G variant predicts occurrence of liver-related events and death in non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2019, 51, e5-e6.	0.9	0

#	ARTICLE	IF	CITATIONS
289	Changes in 13C-aminopyrine breath test predict liver-related events and death in patients with HCV-related previous decompensated child A5 or child A6 to B cirrhosis who achieve SVR after DAA therapy. <i>Digestive and Liver Disease</i> , 2019, 51, e68.	0.9	0
290	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019, 47, 141-168.	4.7	0
291	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S20-S21.	3.7	0
292	Europe's largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4). <i>Journal of Hepatology</i> , 2020, 73, S166-S167.	3.7	0
293	Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance. <i>Journal of Hepatology</i> , 2020, 73, S625-S626.	3.7	0
294	Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort. <i>Journal of Hepatology</i> , 2020, 73, S343.	3.7	0
295	The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI. <i>Digestive and Liver Disease</i> , 2020, 52, e60.	0.9	0
296	PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with non-alcoholic fatty liver. <i>Digestive and Liver Disease</i> , 2020, 52, e8.	0.9	0
297	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with mild-moderate fibrosis, with or without glucose abnormalities: interim results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2020, 52, e26-e27.	0.9	0
298	A cholestatic pattern predicts liver outcomes in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2020, 52, e40.	0.9	0
299	Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. <i>Digestive and Liver Disease</i> , 2020, 52, e41-e42.	0.9	0
300	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
301	The Role of Transient Elastography in NAFLD. , 2021, , 61-74.		0
302	Rare and common ATG7 variants predispose to severe fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, S26-S27.	0.9	0
303	New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM. <i>Digestive and Liver Disease</i> . 2021, 53, S16.	0.9	0
304	OC-06A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, S3-S4.	0.9	0
305	The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries. , 2020, 58, .		0
306	<i>NR1H4</i> rs35724 G&gt;C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
307	Non-invasive Diagnostic Approach to NASH: Biological Markers. , 2020, , 235-256.		0
308	Chemoprevention for hepatocellular carcinoma: the role of statins. Hepatobiliary Surgery and Nutrition, 2013, 2, 1-3.	1.5	0
309	Update on treatment strategies in patients with non-alcoholic fatty liver disease. Current Pharmaceutical Design, 2013, 19, 5167-8.	1.9	0
310	AGILE-3 Score for the diagnosis of advanced fibrosis and for predicting liver-related events in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2022, 54, S17-S18.	0.9	0